Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus

ClinicalTrials.gov ID: NCT00111306

Public ClinicalTrials.gov record NCT00111306. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems

Study identification

NCT ID
NCT00111306
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
510 participants

Conditions and interventions

Interventions

  • epratuzumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2005
Primary completion
Feb 28, 2007
Completion
Feb 28, 2007
Last update posted
Nov 7, 2011

2005 – 2007

United States locations

U.S. sites
13
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Tucson Arizona
Not listed Los Angeles California
Not listed Upland California
Not listed Denver Colorado
Not listed Washington D.C. District of Columbia
Not listed Baltimore Maryland
Not listed New York New York
Not listed The Bronx New York
Not listed Durham North Carolina
Not listed Winston-Salem North Carolina
Not listed Tulsa Oklahoma
Not listed Charleston South Carolina

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00111306, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 7, 2011 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00111306 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →